• Gabriel Alugba, Alexsandra Urhi, Iyanu Victoria Olateju, Henry Onyemarin, Consolata Uzzi, Tolulope Oshiba-Fowode, Elvis Obomanu, Hakeem Adegboyega Popoola, Emeka J Okoronkwo, Emmanuel Ukenenye, Gideon Asaolu, Adeolu Funso Oladunjoye, and Olubunmi Oladunjoye.
• Delta State University, Abraka, Nigeria.
• Medicine (Baltimore). 2022 Dec 2; 101 (48): e31959e31959.

AbstractThe mechanisms of renal pathology in multiple sclerosis (MS) can be related to the disease itself or its treatment. Although kidney disease can be associated with MS, not much has been reported in the literature; hence, our study aimed to describe the prevalence and types of renal diseases and discuss their prognosis in patients with MS. A literature search (2012-2022) was performed using the Scale for the Assessment of Narrative Review Articles. The databases searched included MEDLINE (PubMed) and EMBASE. Fourteen articles from these databases met the inclusion criteria. The inclusion criteria were as follows: publications with full-text access. Articles published in English. Original articles related to renal diseases in MS. The prevalence of renal diseases in MS from the articles obtained ranged from 0.74% to 2.49%. Interferon beta (IFN-β)-associated glomerulonephritis was common among the reviewed articles. Significant improvement and resolution of the pathology were observed after the discontinuation of the offending medication. Renal symptoms in 2 out of 4 cases with renal thrombotic microangiopathy (TMA) induced by interferon-beta progressed to chronic kidney disease, even after the drug was stopped. Other studied renal pathologies included nephrolithiasis secondary to urinary retention and urinary catheter use in patients with MS.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

7 keywords...

hide…